OIS@AAO
Joseph Gardner, president and CEO of Aerpio Therapeutics, acknowledged that his company is not alone in developing Tie2-activating agents to treat retinal disease, but at…
Read MoreEarly reports of AGTC’s lead gene therapy program for X-linked retinoschisis have shown the treatment to be well-tolerated with only mild-to-moderate inflammation that either resolves…
Read MoreAura Biosciences expects to have an active investigational new drug (IND) application for its first-in-class treatment for primary choroidal melanoma early next year and have…
Read MoreCHICAGO—Adverum is a gene therapy company “committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or…
Read MoreSensimed’s Triggerfish is the “first ever Food and Drug Administration-approved contact lens sensor,” said David Bailey, chief executive officer. The lens received US approval in…
Read MoreSmall aperture technology is the only corneal-based presbyopia-correcting procedure that does not rely on the use of “plus power” in the cornea to provide near…
Read MoreThe Raindrop Near Vision Inlay for the treatment of presbyopia boasts a 2 mm diameter, 80% water composition, the same refractive index as the natural…
Read MoreCorneal blindness remains a “significant and growing problem,” said Monty Montoya, chief executive officer, SightLife Surgical. There are more than 10 million corneal blind who…
Read MoreOsmolarity is the one biophysical measurement that “can reliably diagnose dry eye disease (DED) initially and follow the therapeutic response secondarily, said Chris Geddes, PhD,…
Read MoreWhat if there was a therapy that could cut dry eye disease (DED) symptoms in half, improve tear secretion three-fold, and be sustainable for a…
Read MoreFor early medtech players in ophthalmology, making connections for start-up capital can be a challenging task, but at the session “Innovative Financing Options in Ophthalmology”…
Read MoreIvantis is developing “the only minimally invasive microstent for glaucoma that dilates and reconstructs the primary outflow path of the eye,” said president and chief…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.